CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 16 enrolled
Drug / intervention
SLE@Dukebehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05426902
NCT05426902N/ACompleted
CompareCT.gov

Utilizing Qualitative and Quantitative Methods to Understand a New Model of Type 1 and 2 Systemic Lupus Erythematosus (SLE)

Duke University·interventional·Posted Jun 22, 2022·Updated Sep 14, 2023

In Brief

A clinical study evaluating SLE@Duke for Systemic Lupus Erythematosus. Completed, enrolled 16 participants across 1 site.

Detailed Summary

The purpose of this study is to pilot test SLE@Duke, a set of tools to implement the Type 1 \& 2 SLE Model in a clinical setting, as well as to gain an in-depth understanding of providers experiences using the intervention during clinic visits with patients with systemic lupus erythematosus. This record represents Aim 3 of this study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSystemic Lupus Erythematosus
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS)

Timeline

N/ACompletedFinished
20222023202420252026
First PostedJun 22, 2022
Enrollment StartJan 3, 2022
Primary CompletionJun 30, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.0 years ago

Interventions

SLE@Dukebehavioral

SLE@Duke is a set of tools to implement the Type 1 \& 2 SLE Model in a clinical setting. The model includes an Electronic Medical Record (EMR) note template, patient-reported outcome measure, and training on how to discuss Type 1 \& 2 SLE.